Ventricular anti-arrhythmic effects of heptanol in hypokalaemic, langendorff-perfused mouse hearts

Biomedical Reports

Volumn 4, Issue 3, 2016, Pages 313-324

  Tse, Gary ^a   Tse, Vivian ^b   Yeo, Jie Ming ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b MCGILL UNIVERSITY   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Gap junction; Heptanol; Hypokalaemia; Mouse; Sodium channel; Ventricular arrhythmia

Indexed keywords

HEPTANOL;

ACTION POTENTIAL DURATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CERVICAL SPINE DISLOCATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROSTIMULATION; ENDOCARDIUM; EPICARDIUM; HEART ARRHYTHMIA; HEART MUSCLE REFRACTORY PERIOD; HEART RHYTHM; HEART VENTRICLE CONTRACTION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HYPOKALEMIA; ISOLATED HEART; MOUSE; NERVE CONDUCTION VELOCITY; NONHUMAN;

EID: 84977978693     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.577     Document Type: Article

References (58)

1. Saez JC, Berthoud VM, Branes MC, Martinez AD and Beyer EC: Plasma membrane channels formed by connexins: Their regulation and functions. Physiol Rev 83: 1359-1400, 2003.
2. Kanno S and Saffitz JE: The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 10: 169-177, 2001.
3. Antzelevitch C and Burashnikov A: Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin 3: 23-45, 2011.
4. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR and Roden DM: Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 96: 2149-2154, 1997.
5. Krikler DM and Curry PV: Torsade De Pointes, an atypical ventricular tachycardia. Br Heart J 38: 117-120, 1976.
6. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406-412, 1989.
7. Wolbrette DL: Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues. Am J Cardiol 91: 39D-44D, 2003.
8. Fujiki A, Tani M, Yoshida S and Inoue H: Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular reentrant tachycardia. Cardiovasc Drugs Ther 10: 159-166, 1996.
9. Nattel S and Carlsson L: Innovative approaches to antiarrhythmic drug therapy. Nat Rev Drug Discov 5: 1034-1049, 2006.
10. Xing D, Kjølbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH and Martins JB: ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 14: 510-520, 2003.
11. Papp R, Gönczi M, Kovács M, Seprényi G and Végh A: Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischaemic preconditioning. Cardiovasc Res 74: 396-405, 2007.
12. Sabir IN, Killeen MJ, Grace AA and Huang CL: Ventricular arrhythmogenesis: Insights from murine models. Prog Biophys Mol Biol 98: 208-218, 2008.
13. De Vuyst E, Boengler K, Antoons G, Sipido KR, Schulz R and Leybaert L: Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol 163: 469-483, 2011.
14. Killeen MJ, Thomas G, Gurung IS, Goddard CA, Fraser JA, MahautSmith MP, Colledge WH, Grace AA and Huang CL: Arrhythmogenic mechanisms in the isolated perfused hypoka- laemic murine heart. Acta Physiol (Oxf) 189: 33-46, 2007.
15. Sabir IN, Fraser JA, Killeen MJ, Grace AA and Huang CL: The contribution of refractoriness to arrhythmic substrate in hypokalemic Langendorff-perfused murine hearts. Pflugers Arch 454: 209-222, 2007.
16. Christ GJ, Spektor M, Brink PR and Barr L: Further evidence for the selective disruption of intercellular communication by heptanol. Am J Physiol 276: H1911-H1917, 1999.
17. Rüdisüli A and Weingart R: Electrical properties of gap junction channels in guineapig ventricular cell pairs revealed by exposure to heptanol. Pflugers Arch 415: 12-21, 1989.
18. Nelson WL and Makielski JC: Block of sodium current by heptanol in voltageclamped canine cardiac Purkinje cells. Circ Res 68: 977-983, 1991.
19. Tse G, Hothi SS, Grace AA and Huang CL: Ventricular arrhythmogenesis following slowed conduction in heptanoltreated, Langendorff perfused mouse hearts. J Physiol Sci 62: 79-92, 2012.
20. Balasubramaniam R, Grace AA, Saumarez RC, Vandenberg JI and Huang CL: Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1. J Physiol 552: 535-546, 2003.
21. Knollmann BC, Katchman AN and Franz MR: Monophasic action potential recordings from intact mouse heart: Validation, regional heterogeneity, and relation to refractoriness. J Cardiovasc Electrophysiol 12: 1286-1294, 2001.
22. Gussak I, Chaitman BR, Kopecky SL and Nerbonne JM: Rapid ventricular repolarization in rodents: Electrocardiographic manifestations, molecular mechanisms, and clinical insights. J Electrocardiol 33: 159-170, 2000.
23. Fabritz L, Kirchhof P, Franz MR, Eckardt L, Mönnig G, Milberg P, Breithardt G and Haverkamp W: Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Basic Res Cardiol 98: 25-32, 2003.
24. Wu TJ, Lin SF, Weiss JN, Ting CT and Chen PS: Two types of ventricular fibrillation in isolated rabbit hearts: Importance of excitability and action potential duration restitution. Circulation 106: 1859-1866, 2002.
25. Saumarez RC and Grace AA: Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases. Cardiovasc Res 47: 11-22, 2000.
26. Papadatos GA, Wallerstein PM, Head CE, Ratcliff R, Brady PA, Benndorf K, Saumarez RC, Trezise AE, Huang CL, Vandenberg JI, et al: Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci USA 99: 6210-6215, 2002.
27. Wolk R, Kane KA, Cobbe SM and Hicks MN: Regional electrophysiological effects of hypokalaemia, hypomagnesaemia and hyponatraemia in isolated rabbit hearts in normal and ischaemic conditions. Cardiovasc Res 40: 492-501, 1998.
28. Wiener N and Rosenblueth A: The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex 16: 205-265, 1946.
29. Sabir IN, Li LM, Grace AA and Huang CL: Restitution analysis of alternans and its relationship to arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts. Pflugers Arch 455: 653-666, 2008.
30. Mironov S, Jalife J and Tolkacheva EG: Role of conduction velocity restitution and shortterm memory in the development of action potential duration alternans in isolated rabbit hearts. Circulation 118: 17-25, 2008.
31. Watanabe MA, Fenton FH, Evans SJ, Hastings HM and Karma A: Mechanisms for discordant alternans. J Cardiovasc Electrophysiol 12: 196-206, 2001.
32. Banville I and Gray RA: Effect of action potential duration and conduction velocity restitution and their spatial dispersion on alternans and the stability of arrhythmias. J Cardiovasc Electrophysiol 13: 1141-1149, 2002.
33. NICE: Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. NICE technology appraisal guidance [TA314], 2014. http://www.nice.org.uk/guidance/ta314. Accessed December 21, 2015.
34. Adabag AS, Luepker RV, Roger VL and Gersh BJ: Sudden cardiac death: Epidemiology and risk factors. Nat Rev Cardiol 7: 216-225, 2010.
35. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, Mariani R, Gunson K and Jui J: Epidemiology of sudden cardiac death: Clinical and research implications. Prog Cardiovasc Dis 51: 213-228, 2008.
36. Rastegar A and Soleimani M: Hypokalaemia and hyperkalaemia. Postgrad Med J 77: 759-764, 2001.
37. Soar J, Deakin CD, Nolan JP, Abbas G, Alfonzo A, Handley AJ, Lockey D, Perkins GD and Thies K; European Resuscitation Council: European Resuscitation Council guidelines for resuscitation 2005. Section 7. Cardiac arrest in special circumstances. Resuscitation 67 (Suppl 1): S135-S170, 2005.
38. Franz MR, Burkhoff D, Spurgeon H, Weisfeldt ML and Lakatta EG: In vitro validation of a new cardiac catheter technique for recording monophasic action potentials. Eur Heart J 7: 34-41, 1986.
39. Hoffman BF, Cranefield PF, Lepeschkin E, Surawicz B and Herrlich HC: Comparison of cardiac monophasic action potentials recorded by intracellular and suction electrodes. Am J Physiol 196: 1297-1301, 1959.
40. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J and Schnermann J: Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98: 9983-9988, 2001.
41. Osadchii OE, Larsen AP and Olesen SP: Predictive value of electrical restitution in hypokalemiainduced ventricular arrhythmogenicity. Am J Physiol Heart Circ Physiol 298: H210-H220, 2010.
42. Osadchii OE: Effects of ventricular pacing protocol on electrical restitution assessments in guineapig heart. Exp Physiol 97: 807-821, 2012.
43. Osadchii OE: Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundam Clin Pharmacol 24: 547-559, 2010.
44. Brugada P and Wellens HJ: Early afterdepolarizations: Role in conduction block, ‘prolonged repolarization-dependent reexcitation’ and tachyarrhythmias in the human heart. Pacing Clin Electrophysiol 8: 889-896, 1985.
45. Di Diego JM and Antzelevitch C: Pinacidilinduced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry? Circulation 88: 1177-1189, 1993.
46. January CT and Riddle JM: Early afterdepolarizations: Mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64: 977-990, 1989.
47. January CT, Riddle JM and Salata JJ: A model for early afterdepolarizations: Induction with the Ca2+ channel agonist Bay K 8644. Circ Res 62: 563-571, 1988.
48. January CT, Chau V and Makielski JC: Triggered activity in the heart: Cellular mechanisms of early afterdepolarizations. Eur Heart J 12 (Suppl F): 4-9, 1991.
49. Li G, Whittaker P, Yao M, Kloner RA and Przyklenk K: The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovasc Pathol 11: 158-165, 2002.
50. Chen BP, Mao HJ, Fan FY, Bruce IC and Xia Q: Delayed uncoupling contributes to the protective effect of heptanol against ischaemia in the rat isolated heart. Clin Exp Pharmacol Physiol 32: 655-662, 2005.
51. Sun B, Qi X and Jiang J: Heptanol decreases the incidence of ischemiainduced ventricular arrhythmias through altering electrophysiological properties and connexin 43 in rat hearts. Biomed Rep 2: 349-353, 2014.
52. Kuo CS, Munakata K, Reddy CP and Surawicz B: Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 67: 1356-1367, 1983.
53. Shaw RM and Rudy Y: Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res 81: 727-741, 1997.
54. Rohr S: Role of gap junctions in the propagation of the cardiac action potential. Cardiovasc Res 62: 309-322, 2004.
55. Fast VG and Kléber AG: Block of impulse propagation at an abrupt tissue expansion: Evaluation of the critical strand diameter in 2-and 3-dimensional computer models. Cardiovasc Res 30: 449-459, 1995.
56. Leon LJ and Roberge FA: Directional characteristics of action potential propagation in cardiac muscle. A model study. Circ Res 69: 378-395, 1991.
57. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM and Garson A Jr: The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 84: 1136-1144, 1991.
58. Linker NJ, Colonna P, Kekwick CA, Till J, Camm AJ and Ward DE: Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol 69: 634-638, 1992.